Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment
Comments Follow Plans For Novartis To Spin Sandoz
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.